0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-04-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP SC584289 2023-04-01 2024-03-31 SC584289 2024-03-31 SC584289 2023-03-31 SC584289 2022-04-01 2023-03-31 SC584289 2023-03-31 SC584289 2022-03-31 SC584289 bus:Director1 2023-04-01 2024-03-31 SC584289 core:WithinOneYear 2023-03-31 SC584289 core:ShareCapital 2024-03-31 SC584289 core:ShareCapital 2023-03-31 SC584289 core:RetainedEarningsAccumulatedLosses 2023-03-31 SC584289 bus:SmallEntities 2023-04-01 2024-03-31 SC584289 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 SC584289 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 SC584289 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 SC584289 bus:FullAccounts 2023-04-01 2024-03-31 SC584289 core:ParentEntities 2023-04-01 2024-03-31
COMPANY REGISTRATION NUMBER: SC584289
Karma Cardiology Limited
Filleted Unaudited Financial Statements
For the year ended
31 March 2024
Karma Cardiology Limited
Statement of Financial Position
31 March 2024
2024
2023
Note
£
£
Current assets
Cash at bank and in hand
100
9,454
Creditors: amounts falling due within one year
4
40
----
-------
Net current assets
100
9,414
----
-------
Total assets less current liabilities
100
9,414
----
-------
Capital and reserves
Called up share capital
100
100
Profit and loss account
9,314
----
-------
Shareholder funds
100
9,414
----
-------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 24 October 2024 , and are signed on behalf of the board by:
Dr K J Williams
Director
Company registration number: SC584289
Karma Cardiology Limited
Notes to the Financial Statements
Year ended 31 March 2024
1. General information
The company is a private company limited by shares, registered in Scotland. The address of the registered office is 33 Kittoch Street, Village, East Kilbride, G74 4JW, Scotland.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Consolidation
The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.
4. Creditors: amounts falling due within one year
2024
2023
£
£
Other creditors
40
----
----
5. Related party transactions
During the year the company entered into the following transactions with related parties:
Transaction value
2024
2023
£
£
KJW Clinical Research Limited
9,298
-------
----
Control:- The company was under the control of Dr K J Williams throughout the period under review. Dr K J Williams is the sole Director . Transactions:- During the year the company paid dividends of £9,298 to the company's parent undertaking KJW Clinical Research Ltd.
6. Controlling party
The company's ultimate parent undertaking at the statement of financial position date was KJW Clinical Research Limited, a company incorporated in Scotland.